Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial.
OBJECTIVE This study aim ed to evaluate the effects of statin therapy on serum levels of antibodies to several specific heat shock proteins ( HSPs ) in dyslipidemic patients . DESIGN AND METHODS Participants ( n=102 ) were treated with simvastatin ( 40mg/day ) , or placebo in a r and omized , double-blind , placebo-controlled , cross-over trial . Anti-HSP60 , 65 , 70 , and hs-CRP levels were measured before and after each treatment period . Seventy-seven subjects completed the study . RESULTS Treatment with simvastatin was associated with significant reductions in serum anti-HSP60 , 65 , and 70 titers in the dyslipidemic patients ( 10 % , 14 % , and 15 % decrease , respectively ) ( p<0.001 ) . There have been previous reports of reductions in serum CRP with statin treatment , and although median CRP levels were 9 % lower on simvastatin treatment , this did not achieve statistical significance . CONCLUSION While it is unclear whether HSP antibodies are directly involved in atherogenesis , our findings suggest that simvastatin inhibits autoimmune responses that may contribute to the development of cardiovascular disease
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .